导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.86% | 4035/4762 |
| 近一周 | -2.69% | 4145/5451 |
| 近一月 | -1.06% | 1011/5408 |
| 近一季 | -1.44% | 1209/5218 |
| 近半年 | -5.85% | 3097/4907 |
| 近一年 | -12.71% | 3568/4387 |
| 近两年 | 25.96% | 2456/2950 |
| 近三年 | 10.75% | 1734/2249 |
| 成立以来 | 94.03% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-14.81% 4681/4961 |
3.26% 2949/5312 |
- - |
- - |
| 2025 | 9.36% 2868/4813 |
-5.90% 3327/3635 |
5.99% 508/4076 |
7.83% 3432/4524 |
1.69% 1262/4813 |
| 2024 | 27.88% 175/3463 |
-3.51% 1515/2808 |
-4.82% 1563/3014 |
43.16% 17/3129 |
-2.74% 2169/3463 |
| 2023 | 0.44% 411/2656 |
2.35% 1367/2280 |
-0.86% 422/2385 |
6.51% 70/2515 |
-7.07% 2037/2655 |
| 2022 | -19.50% 855/2207 |
-15.60% 1052/1919 |
2.10% 1359/2016 |
-13.85% 985/2113 |
8.44% 263/2208 |
| 2021 | -9.32% 1076/1822 |
-12.43% 1147/1255 |
1.71% 1037/1330 |
-0.36% 492/1466 |
2.17% 667/1822 |
| 2020 | 13.96% 800/1250 |
-12.86% 903/1028 |
8.71% 815/1067 |
17.46% 103/1164 |
2.41% 989/1184 |
| 2019 | 42.96% 199/1092 |
40.62% 52/754 |
-2.45% 352/804 |
-3.24% 733/850 |
7.70% 407/918 |
| 2018 | -26.33% 382/834 |
- - |
- - |
- - |
-9.86% 166/691 |
| 2017 | 10.13% 303/714 |
- - |
- - |
- - |
- - |
| 2016 | -12.85% 309/605 |
- - |
- - |
- - |
- - |
| 2015 | -22.69% 303/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证800证券保险指数(LOF)A VS. 长安沪深300非周期A(740101) |